ELPIS II Misses Primary Endpoint, Secondary MACE Signal Fails to Rescue LGVN Thesis

What happened

Longeveron announced that its ELPIS II Phase 2b trial in HLHS did not meet the primary endpoint of increased right ventricular ejection fraction at month 12. However, a pre-specified secondary endpoint of major adverse cardiac events achieved statistical significance, with 1 event in the laromestrocel arm versus 8 in the standard of care arm (p=0.043). The company is framing this as evidence of potential clinical benefit, but the trial enrolled only 40 infants and secondary endpoints from a failed primary are exploratory at best. This update does not address the company’s severe cash constraints, with runway only into late Q1 2026, nor the looming Nasdaq minimum bid compliance deadline of March 23, 2026. While the MACE data may invite partnership speculation, the investment thesis remains dominated by financing risk and heavy dilution.

Implication

Investors should not overinterpret the MACE benefit, as it is a secondary endpoint in a small trial that missed its primary efficacy measure. Any potential regulatory path would require additional confirmatory trials, which the company cannot fund without substantial dilution or a partnership. The company still faces an imminent cash crunch and Nasdaq delisting risk, likely forcing a reverse split or deeply discounted financing. If a funding event is announced alongside this data, it may provide temporary relief but will further dilute existing shareholders. Given the unchanged balance-sheet distress and uncertain regulatory outlook, the STRONG SELL thesis remains intact, and any speculative buying should be treated as a high-risk trade with tight risk controls.

Thesis delta

The new data introduces a modest positive signal on a secondary endpoint, but it does not change the core thesis. The primary endpoint miss undermines the original HLHS BLA and PRV story, while financial and listing risks remain acute. Therefore, the STRONG SELL rating and conviction remain unchanged, though the probability of a near-term partnership may inch slightly higher.